GlassScriptPhysician profile
Bernard J Steyer
NPI 1699741454
$2,480.07
in general payments reported to CMS, 2019-2025
30 companies · $463 in 2025
The $463 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $242 · 2021: $190 · 2022: $199 · 2023: $418 · 2024: $491 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $900.74 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.88 | 2019-2025 | Ofev |
| Insmed, INC. | $195.09 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $153.88 | 2022-2025 | Fasenra, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $105.26 | 2023-2025 | Dupixent |
| Amgen INC. | $87.25 | 2024-2025 | Tezspire, Tavneos |
| Inari Medical, INC. | $85.13 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mylan Specialty L.P. | $78.87 | 2019-2020 | |
| Intuitive Surgical, INC. | $49.03 | 2021 | |
| Genzyme Corporation | $48.94 | 2023-2024 | |
| Electromed, INC. | $47.58 | 2023 | Smartvest |
| Gilead Sciences, INC. | $37.26 | 2019 | |
| Pfizer INC. | $34.77 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.78 | 2024 | |
| Novartis Pharmaceuticals Corporation | $29.46 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.98 | 2024 | Cuvitru |
| Sanofi Pasteur INC. | $27.26 | 2025 | |
| Merck Sharp & Dohme LLC | $26.01 | 2025 | Zerbaxa |
| Verona Pharma, INC. | $24.86 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $23.36 | 2025 | Yupelri |
| Baxter Healthcare | $22.65 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $22.24 | 2019 | |
| Pulmonx Corporation | $21.89 | 2020 | |
| Resmed Corp | $21.76 | 2019 | |
| Fisher & Paykel Healthcare INC | $21.75 | 2023 | Fisher & Paykel Healthcare |
| Erbe USA INC | $21.00 | 2024 | |
| United Therapeutics Corporation | $20.07 | 2023 | Orenitram |
| Advanced Respiratory, INC | $18.54 | 2019 | |
| Chiesi USA, INC. | $16.77 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Steyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.